All Stories

  1. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  2. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  3. Factors associated with early, late, and very late stent thrombosis among patients with acute coronary syndrome undergoing coronary stent placement: analysis from the ATLAS ACS 2-TIMI 51 trial
  4. Global Burden of Cardiovascular Diseases and Risks, 1990-2022
  5. Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping Review
  6. Global burden of peripheral artery disease and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  7. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
  8. The Relationship Between the Age of First Acute Coronary Syndrome Episode and Internal Migration
  9. External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial
  10. Association of D-dimer with short-term risk of venous thromboembolism in acutely ill medical patients: A systematic review and meta-analysis
  11. Factors associated with recurrent spontaneous coronary artery dissection: a systematic review and meta-analysis
  12. Systematic Review and Meta-Analysis of Thromboprophylaxis with Heparins Following Intracerebral Hemorrhage
  13. Intracranial Pressure Monitoring in Moderate Traumatic Brain Injury: A Systematic Review and Meta-Analysis
  14. ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
  15. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis
  16. Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial
  17. Abstract P199: Association Of High Left Ventricular Ejection Fraction With Incident Heart Failure, And Impact Of Adiposity On Ejection Fraction
  18. MIGRAINE HEADACHE IN PATIENTS WITH SPONTANEOUS CORONARY ARTERY DISSECTION: A REPORT OF THE ISCAD REGISTRY
  19. Early and late recurrent cardiovascular events among high‐risk patients with an acute coronary syndrome: Meta‐analysis of phase III studies and implications on trial design
  20. Clinical outcomes of pharmacological thromboprophylaxis among patients with intracerebral hemorrhage: Systematic review and meta-analysis
  21. Association of Cholesterol Efflux Capacity with Adverse Cardiovascular Outcomes: A Meta-Analysis†
  22. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial
  23. Early and Late Recurrent Cardiovascular Risk in Patients With Recent Acute Coronary Syndrome: Meta-Analysis and Implications in Trial Design†
  24. Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
  25. Association between obesity grade and the age of the first acute coronary syndrome: A cross-sectional observational study
  26. Cholesterol Efflux Capacity and Measurement Assays: A Novel Biomarker of High-Density Lipoprotein (HDL) Function
  27. Biological Basis and Proposed Mechanism of Action of CSL112 (Apolipoprotein A-I [Human]) for Prevention of Major Adverse Cardiovascular Events in Patients post Myocardial Infarction
  28. Evaluation of Cardiac Troponin and Adverse Outcomes After Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis
  29. Effect of Azithromycin and Hydroxychloroquine in Patients Hospitalized with COVID‐19: Network Meta‐Analysis of Randomized Controlled Trials
  30. Independent and incremental prognostic value of D-dimer in hospitalized COVID-19 patients
  31. Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients
  32. ASSOCIATION OF CHOLESTEROL EFFLUX CAPACITY WITH ADVERSE CARDIOVASCULAR OUTCOMES - A META-ANALYSIS
  33. EARLY AND LATE RECURRENT CARDIOVASCULAR RISK IN PATIENTS WITH RECENT ACUTE CORONARY SYNDROME - META-ANALYSIS AND IMPLICATIONS IN TRIAL DESIGN
  34. Association between red blood cell distribution width and mortality and severity among patients with COVID‐19: A systematic review and meta‐analysis
  35. The Role of Interleukin-27 in Atherosclerosis: A Contemporary Review
  36. COVID-19: A double threat to takotsubo cardiomyopathy and spontaneous coronary artery dissection?
  37. Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis
  38. Extended Thromboprophylaxis with Betrixaban or Rivaroxaban for Acutely Ill Hospitalized Medical Patients
  39. Differential effect of ticagrelor on irreversible harms in diabetes
  40. Attention and citation: Common interests of researchers and journals
  41. Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial)
  42. Coronary artery tortuosity
  43. Effect of Vitamins and Dietary Supplements on Cardiovascular Health
  44. Machine learning to predict venous thrombosis in acutely ill medical patients
  45. The AngelMed Guardian® System in the Detection of Coronary Artery Occlusion: Current Perspectives
  46. Spontaneous coronary artery dissection managed with a conservative or revascularization approach
  47. Prognostic Value of Biomarkers in Cardiac Allograft Vasculopathy following Heart Transplantation: A Literature Review
  48. Smartwatch for the Detection of Atrial Fibrillation
  49. Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study
  50. Spontaneous coronary artery dissection and associated myocardial bridging: Current evidence from cohort study and case reports
  51. Risk Factors, Imaging Findings, and Sex Differences in Spontaneous Coronary Artery Dissection
  52. Spontaneous coronary artery dissection and its association with takotsubo syndrome: Novel insights from a tertiary center registry
  53. Social media optimization in medicine: A journal's perspective
  54. Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
  55. PARADOXICAL PROTECTIVE EFFECT OF OBESITY ON THE RISK OF VENOUS THROMBOEMBOLISM: OBSERVATIONS FROM APEX TRIAL
  56. Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients
  57. Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy
  58. Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: Updated meta-analysis of randomized trials
  59. Chikungunya Virus Infection-related Rhabdomyolysis: A Case Report
  60. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
  61. Eosinophilic Inflammation In Spontaneous Coronary Artery Dissection: Agent Provocateur Or Innocent Bystander?
  62. Eosinophilic inflammation in spontaneous coronary artery dissection: A potential therapeutic target?
  63. Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial
  64. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial
  65. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism
  66. Continuous Thoracic Paravertebral Block as Perioperative Analgesia for Off-Pump Coronary Artery Bypass Grafting
  67. D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)
  68. P1623Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial
  69. P251Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial
  70. 4321Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial
  71. 1460Effect of the INR stability characteristics on bleeding events among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial
  72. P6072Characterization of major and clinically relevant non-major bleeding in the APEX trial
  73. 2160Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial
  74. 109Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis
  75. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the Apex Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended...
  76. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention
  77. Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis
  78. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients following percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
  79. Scleral exposure alterations following Le Fort I osteotomy (with and without maxillary impaction) in skeletal class III patients: A before-and-after clinical trial
  80. Dual antithrombotic plus adjunctive antiinflammatory therapy to improve cardiovascular outcome in atrial fibrillation patients with concurrent acute coronary syndrome: A triple-pathway strategy
  81. Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials
  82. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
  83. Association of Low Hemoglobin with Symptomatic Venous Thromboembolism in Acutely Ill Hospitalized Medical Patients: an APEX Trial Substudy
  84. COMPARATIVE EFFICACY AND SAFETY OF RIVAROXABAN-BASED DUAL-PATHWAY ANTITHROMBOTIC THERAPY VERSUS DUAL ANTIPLATELET THERAPY: A POOLED ANALYSIS OF CONTEMPORARY RANDOMIZED CONTROLLED TRIALS
  85. High-Density Lipoprotein-Targeted Therapy for Coronary Heart Disease: is the HDL Hypothesis Operational or Defunct?
  86. Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial
  87. Characterisation of Access Site Versus Non-Access Site Bleeding After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation
  88. Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI
  89. Surface Microbiology of Smartphone Screen Protectors Among Healthcare Professionals
  90. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients
  91. Letter by Chi and Marszalek Regarding Article, “Composite End Points in Clinical Research: A Time for Reappraisal”
  92. Symptomatic Event Reduction with Extended-Duration Betrixaban in Acute Medically Ill Hospitalized Patients
  93. Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial
  94. Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria
  95. N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy
  96. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
  97. P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy
  98. P4316N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy
  99. P5600History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial
  100. P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy
  101. P6112Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial
  102. P5599Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis
  103. P1551D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely Ill medical patients: insights from the APEX trial
  104. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials
  105. Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
  106. The risk of stroke among acutely ill hospitalized medical patients: lessons from recent trials on extended-duration thromboprophylaxis
  107. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification
  108. Commentary: Extended-Duration betrixaban reduces the risk of stroke versus standard-Dose enoxaparin among hospitalized medically Ill patients
  109. Erratum
  110. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors
  111. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
  112. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction
  113. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment StrategyClinical Perspective
  114. Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill PatientsClinical Perspective
  115. Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)
  116. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
  117. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis
  118. THE ASSOCIATION BETWEEN LEFT VENTRICULAR MASS AND MEASURES OF INFARCT SIZE IN ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE EMBRACE STEMI CLINICAL TRIAL
  119. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention
  120. d-Dimer elevation and adverse outcomes
  121. Scleroderma and failed response to alefacept